DiaMedica Therapeutics to Participate in 11th Annual Craig-Hallum Alpha Select Conference
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that President and CEO Rick Pauls and CFO Scott Kellen will participate in the Craig-Hallum Alpha Select Conference on November 17, 2020. The conference will be held virtually due to social distancing measures amid the Covid-19 pandemic. Interested institutional investors should coordinate with their Craig-Hallum representative to arrange meetings. DiaMedica is focused on developing innovative treatments for chronic kidney diseases and neurological disorders.
- None.
- None.
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for chronic kidney diseases and neurological disorders, today announced its President and CEO, Rick Pauls, and Chief Financial Officer, Scott Kellen, are scheduled to participate in the Craig-Hallum Alpha Select Conference, which is being held as a virtual event on November 17, 2020.
Meetings will take place virtually on November 17, 2020 given the ongoing call for social distancing due to the Covid-19 pandemic. Interested institutional investors should contact their Craig-Hallum sales representative to schedule a meeting.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”
For more information, please visit www.diamedica.com.
